BRIEF-Exelixis and Ipsen enter into exclusive licensing agreement
March 01, 2016 at 01:21 AM EST
* Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States, Canada and Japan
